United States Estrogen Receptor Positive (ER+) Breast Cancer Report 2016 - Market Insights, Epidemiology and Market Forecast, 2023 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Estrogen Receptor Positive (ER+) Breast Cancer - Market Insights, Epidemiology and Market Forecast-2023_United States" report to their offering.

Estrogen Receptor Positive (ER+) Breast Cancer - Market Insights, Epidemiology and Market Forecast-2023- US Reports provides an overview of the disease and global market size of the Estrogen Receptor Positive (ER+) Breast Cancer for the United States.

It also includes global historical and forecasted epidemiological data for the diagnosed incident cases of Estrogen Receptor Positive (ER+) Breast Cancer from 2013-2023.

The forecasted patient population of ER+ breast cancer will increase at a CAGR of 2.03% from 2015 to 2023 and the worldwide ER+ breast cancer market is estimated to be 2.86 billion by 2023. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

Scope

- Report covers the disease overview, current treatment options, prescription drugs and emerging therapies.

- The Report also covers the detailed global historical and forecasted epidemiological data covering United States from 2013-2023.

- It also provides Market size of Estrogen Receptor Positive (ER+) Breast Cancer for United States and forecasted Market size to 2023.

Key Topics Covered:

Table of Contents

1 Report Introduction

2 Executive Summary

- Key Findings

3 ER+ Breast Cancer Market Overview at a Glance

- Worldwide Market Size of ER+ Breast Cancer in 2013

- Worldwide Market Size of ER+ Breast Cancer in 2023

4 Treatment Landscape

- Treatment Options by Stage

- Stage IA

- Stage IB

- Stage IC

- Stage IIA

- Stage IIB, Stage IIC, Stage IIIA, Stage, IIIB, Stage IIIC, Stage IV

- Treatment Algorithm

- Treatment Follow-Up

5 Epidemiology and Patient Population

- Key Findings

- Overview

- Disease Classification

- Population and Forecast Methodology

- Total Incident Cases

- Diagnosed Drug Treated Population

- Percentage Diagnosed

- Percentage Drug Treated

6 Current Medical Practice and Therapies in Use

- Key Findings

- Overview of ER+ Breast Cancer

- Treatment Goals

- Currently Medical Practice

- Overview of ER+ Breast Cancer Drug Classification

- Prescription Drugs, Dosing & Route

7 Emerging Therapies

- Key Findings

- Unmet need

- Late Stage Pipeline Overview

- Expected Launch date of these therapies in United States

- Late Stage Pipeline Analysis

- Efficacy & Safety Results

8 United States Market Assessment

- Key Findings

- United States Market Forecast

- United States Market Size

- Market Driver and Constraints

- Factors Driving the Market for ER+ Breast Cancer

- Factors Constraining the Market for ER+ Breast Cancer

9 Consulting Services

Companies Mentioned

- Sanofi-Aventis

- Astellas Pharma

- Pfizer Inc.

- Novartis Pharmaceuticals

- Astrazeneca, Inc.

- Curis Inc.

- Chidamide

- Chipscreen Biosciences

For more information visit http://www.researchandmarkets.com/research/4xm4qp/estrogen_receptor

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Women's Health

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Women's Health